Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.48 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.47 |
| ▸ | GJB2 | P29033 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8928604 | 1.00 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL9167095 | 1.00 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1775254 | 1.00 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13038862 | 1.00 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12380695 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8721436 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6265877 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8721432 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2290681 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1776601 | 0.95 | PTPN1 (0.45) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943584-B2 | Medicinal composition containing diabetes remedy | SANKYO COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1589023-B1 | OLIGOSACCHARIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7632930-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080194495-A1 | Oligosaccharide Derivative | HONDA TAKESHI | 2008-08-14 | — | — | US | disclosed |
| US-7361744-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1792620-A1 | MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY | Sankyo Company, Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20060025350-A1 | Oligosaccharide derivative | SANKYO COMPANY, LIMITED (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1589023-A1 | OLIGOSACCHARIDE DERIVATIVE | Sankyo Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
| EP-0369182-B1 | Antitumour saccharide conjugates | DEUTSCHES KREBSFORSCH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0369182-A1 | Antitumour saccharide conjugates | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1990004597-A1 | TUMOR-INHIBITING SACCHARIDE CONJUGATES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | SSTR1 879/4885SSTR2 1191/4885SSTR4 457/4885 |
| US-20060025350-A1 | Oligosaccharide derivative | MAN1B1, FUT6, MAN2A1 | SSTR1 373/4885SSTR2 379/4885SSTR4 275/4885 |
| US-20080194495-A1 | Oligosaccharide Derivative | MAN1B1, FUT6, MAN2A1 | SSTR1 373/4885SSTR2 379/4885SSTR4 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.